- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership | ||
| Do | Cellares and TScan to assess automated manufacturing of TSC-101 therapy | ||
| Do | Regeneron and CytomX extend cancer therapy partnership to $4bn deal | ||
| Mi | US lawmakers reveal policy to curb collaboration with Chinese biotech | ||
| Mi | Contraline secures $92.5m to push male contraceptive into late-stage trials | ||
| Mi | AbbVie receives EC approval for Aquipta to treat migraine | ||
| Mi | Roche's giredestrant secures FDA priority review for breast cancer | ||
| Di | ASCO26: In vivo oncology approaches continue to show promise | ||
| Di | ASCO26: Blood cancer readouts take centre stage | ||
| Di | BMS secures FDA acceptance for Camzyos sNDA | ||
| Di | Servier to acquire Edgewise's muscular dystrophy business for $2.65bn | ||
| Mo | ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise | ||
| Mo | ASCO26: key readouts in lung cancer | ||
| Mo | ASCO26: BMS and J&J debut shining multiple myeloma data | ||
| Mo | Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide | ||
| Mo | FDA approves AstraZeneca's Imfinzi-BCG combination for NMIBC therapy | ||
| 29.05. | GSK's Nucala secures NICE COPD endorsement | ||
| 29.05. | Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal | ||
| 29.05. | FDA grants priority review for Sanofi's venglustat NDA | ||
| 28.05. | FDA oncology roundup: AbbVie's rare cancer approval, AstraZeneca in breast cancer limbo | ||
| 27.05. | California startup Protuoso raises $9.5m for "mix-and-match" drug platform | ||
| 27.05. | Kardigan targets IPO to support cardiology pipeline progression | ||
| 27.05. | Autobahn's elunetirom receives FDA fast track designation to treat adjunctive bipolar | ||
| 27.05. | SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative | ||
| 26.05. | EMA recommends approvals for both oral and high-dose pen of Wegovy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.